Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-10-29
2009-10-13
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S258000
Reexamination Certificate
active
07601717
ABSTRACT:
Disclosed herein are analogs of tetrahydrobiopterin, compositions containing the same, and methods of treating an individual suffering from a condition responsive to tetrahydrobiopterin by administration of the analog. These analogs are contemplated for use wherever tetrahydrobiopterin is currently used to treat conditions responsive to tetrahydrobiopterin therapies.
REFERENCES:
patent: 4540783 (1985-09-01), Viscontini
patent: 4550109 (1985-10-01), Folkers et al.
patent: 4587340 (1986-05-01), Nichol et al.
patent: 4701455 (1987-10-01), Nichol et al.
patent: 4937342 (1990-06-01), Kurono et al.
patent: 4957924 (1990-09-01), Beauchamp
patent: 5037981 (1991-08-01), Kurono et al.
patent: 5043339 (1991-08-01), Beauchamp
patent: 6162806 (2000-12-01), Arai et al.
patent: 6844343 (2005-01-01), Pfleiderer et al.
patent: 6858612 (2005-02-01), Pfleiderer et al.
patent: 2005/0137141 (2005-06-01), Hilfinger
patent: 2006/0040946 (2006-02-01), Oppenheimer et al.
patent: 2006/0194800 (2006-08-01), Wadsworth et al.
patent: 2007/0167353 (2007-07-01), Hilfinger et al.
patent: 2007/0244322 (2007-10-01), Moser et al.
patent: 2007/0270581 (2007-11-01), Jungles et al.
patent: WO 2006/063215 (2006-06-01), None
patent: WO 2007/067570 (2007-06-01), None
patent: WO 2008/089008 (2008-07-01), None
Li, et al., J. Pharm Sci., vol. 97, No. 3, Mar. 2008, 1109-1134.
Aungst, et al., Prodrugs to Reduce Presystemic Metabolism, 339-355, 2007.
Gaucher, et al., Org. Biomol. Chem., 2004, 2, 345-357.
Bjelakovic, et al., Medicine & Biology, vol. 11, No. 2, 2004, 49-54.
Anand, et al., “Current prodrug strategies via membrane transporters/receptors,”Expert Opin. Biol. Ther., 2(6) :607-620 (2002.
Cho, et al., “Tepidopterin, 1-O-(L-threo-biopterin-2′-yl)-β-N-acetylglucosamine fromChlorobium tepidum,”Biochim. Biophys. Acta, 1379:53-60 (1998).
De Clercq, et al., “Antiviral prodrugs—the development of successful prodrug strategies for antiviral chemotherapy”Brit. J Pharmacol., 147:1-11 (2006).
Gomes, et al., “Cyclization-activated Prodrugs,”Molecules, 12:2484-2506 (2007).
Hanaya, et al., “First synthesis of tepidopterin [2′-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-L-threo-biopterin],”Carbohydrate Res., 342 :2159-2162 (2007).
Kim, et al., “Biphenyl Hydrolase-Like Protein as Valacyclovir Hydrolase,”J Biol Chem, 278:25348-25356 (2003).
Kim, et al., “A Novel Nucleoside Prodrug-Activating Enzyme: Substrate Specificity of Biphenyl Hydrolase-Like Protein,”Mol. Pharmaceut., 1(2); 117-127 (2004).
Kim, et al., “Structure and Specificity of a Human Valacyclovir Activating Enzyme: A Homology Model of BPHL,”Mol. Pharmaceut., 1(6):434-446 (2004).
Lin, et al., “Structure of Solfapterin (erythro-Neopterin-3′-D-2-Deoxy-2-Aminoglucopyranoside) Isolated from the Thermophilic ArchaebacteriumnSulfolobus solfataricus,”J Bacteriol., 1396-1398 (1988).
Lorenzi, et al., “Amino Acid Ester Prodrugs of 2-Bromo-5,6-dichloro-1-(β-D-ribofuranosyl)benzimidazole Enhance Metabolic Stability in Vitro and in Vivo,”J Pharmacol. Exp. Therapeut., 314:883-890 (2005).
Purifoy, et al., “Review of Research Leading to New Anti-Herpesvirus Agents in Clinical Development: Valaciclovir Hydrochloride (256U, the L-Valyl Ester of Acyclovir) and 882C, a Specific Agent for Varicella Zoster Virus,”J Med Virol Supp, 1:139-145 (1993).
Song, et al., “Amino Acid Ester Prodrugs of the Anticancer Agent Gemcitabine: Synthesis, Bioconversion, Metabolic Bioevasion, and hPEPT1-Mediated Transport,”Mol. Pharmaceut., 2(2):157-167 (2005).
Friedrichsen, et al., “Synthesis of analogs of -valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells,”Eur. J. Pharma. Sci., 16:1-13 (2002).
Berch Mark L
BioMarin Pharmaceutical Inc.
Jaisle Cecilia M
Jones Day
LandOfFree
Pterin analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pterin analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pterin analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4075290